Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q3 2021 · 10-Q
Revenue$30.77M$30.77M−68.9% vs Q3 2020 Net Income-$58.41M-$58.41MN/M vs Q3 2020 EPS Diluted-$1.37-$1.37N/M vs Q3 2020 Operating Income-$57,348,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$61,201,000N/M Margins · derivedOperating margin-186.4%−200.5 pt vs Q3 2020
Net margin-189.8%−198.7 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 2, 2021 · 33 d after period end